These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 17005316

  • 1. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y, Ichikawa T.
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA.
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [Abstract] [Full Text] [Related]

  • 5. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M.
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [Abstract] [Full Text] [Related]

  • 6. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
    Kravchick S, Peled R, Dorfman D, Agulansky L, Ben-Dor D, Cytron S.
    Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
    [Abstract] [Full Text] [Related]

  • 10. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M.
    Urol J; 2009 Sep; 6(3):182-8. PubMed ID: 19711272
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J, Planas J, Ramirez C, Gómez E, Raventós CX, Placer J, Catalán R, de Torres IM.
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [Abstract] [Full Text] [Related]

  • 12. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M, Suzuki H, Kamiya N, Imamoto T, Komiya A, Ueda T, Watanabe M, Shiraishi T, Ichikawa T.
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [Abstract] [Full Text] [Related]

  • 13. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G, Marberger M, Remzi M, Grösser P, Unterlechner J, Haidinger G, Zidek T, Preyer M, Micksche M, Gsur A.
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G, Gao JP, Cao XL, Hong BF, Tang J.
    Zhonghua Wai Ke Za Zhi; 2006 Mar 15; 44(6):379-81. PubMed ID: 16638346
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer detection by prostate-specific antigen-related parameters.
    Segawa N, Gohji K, Iwamoto Y, Ueda H, Katsuoka Y.
    Hinyokika Kiyo; 2003 Jul 15; 49(7):405-10. PubMed ID: 12968483
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
    Zagars GK, Pollack A, von Eschenbach AC.
    Urology; 1997 Mar 15; 49(3):327-34. PubMed ID: 9123693
    [Abstract] [Full Text] [Related]

  • 20. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M.
    Prostate; 2001 Apr 15; 47(1):52-8. PubMed ID: 11304729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.